London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here

Come to London


WATCH to find out why

Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.

1 year results after the implantation of the Micro-Stent CyPass

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Glaucoma I

Session Date/Time: Sunday 14/09/2014 | 08:00-09:30

Paper Time: 08:36

Venue: Auditorium

First Author: : M.Rau GERMANY

Co Author(s): :                  

Abstract Details


To evaluate the safety and clinical outcomes of an ab interno supraciliary implant (CyPass Micro-Stent, Transcend Medical, Inc., Menlo Park, CA, USA) in patients with open-angle glaucoma (OAG) undergoing cataract surgery or as a standalone procedure.


Augenklinik Cham, Germany


Eyes (n=33) were enrolled in a single site (Cham, Germany) by the investigator. The majority of the eyes (n=24) were undergoing concomitant cataract surgery. In those cases, the supraciliary device was implanted immediately following the cataract surgery portion of the procedure through the same corneal incision. Medications were stopped following the procedure and re-introduced at the investigator’s discretion, depending on the intraocular pressure (IOP) target of the patient. Main outcomes were adverse events, IOP changes, and number of IOP-lowering medications.


At baseline, subjects had a mean IOP of 23.3 ± 6.8 mmHg and were taking a mean of 1.9 ± 1.1 IOP-lowering medications. All implants were placed successfully, and no major sight-threatening adverse events occurred. At month 12, subjects (n=22) had a mean IOP of 14.6 ± 4.3 mmHg, representing a paired 28% reduction, with mean medication usage reduced to 0.7 ± 0.9.


Implantation of the CyPass Micro-Stent in combination with cataract surgery or as a standalone procedure reliably results in minimal complications and reduction of IOP and IOP-lowering medications at 12 months postoperatively.

Financial Interest:


Back to previous